The ART of tumor immune escape

Erik Wennerberg, Sumit Mukherjee, Ricardo M. Sainz, Brendon M. Stiles

Research output: Contribution to journalArticlepeer-review

Abstract

We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD+) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1.

Original languageEnglish (US)
Article number2076310
JournalOncoImmunology
Volume11
Issue number1
DOIs
StatePublished - 2022

Keywords

  • CD38
  • CD8 T cells
  • immune escape
  • lung cancer
  • mono-ADP-ribosylation
  • NAD-induced cell death
  • P2X7 receptor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'The ART of tumor immune escape'. Together they form a unique fingerprint.

Cite this